of WHO guidelines during pandemics: A Global Survey.

Authors and Affiliation

- 4 Melody Sakala^{1,2*}, Cheryl Johnson^{3*}, James Chirombo^{1,2}, Jilian A. Sacks³, Rachel Baggaley³ and
- 5 Titus Divala¹.

1

3

- 6 1 Malawi Liverpool Wellcome Programme, Blantyre, Malawi
- 7 2 Kamuzu University of Health Sciences, Blantyre, Malawi
- 8 3 World Health Organisation, Geneva, Switzerland
- 9 *Corresponding authors
- 10 Email: msakala@mlw.mw (MS)
- 11 Email: johnsonc@who.int (CJ)

12 Abstract

13

Introduction

- 14 The widespread use of antigen-detection rapid diagnostic tests (Ag-RDTs) has revolutionized
- 15 SARS-CoV-2 (COVID-19) testing, particularly through the option of self-testing. The full extent
- of Ag-RDT utilization for self-testing, however, remains largely unexplored. To inform the
- 17 development of WHO guidance on COVID-19 self-testing, we conducted a cross-sectional
- survey to gather the views and experiences of policy makers, researchers, and implementers
- 19 worldwide.

Methods

The survey was shared through professional networks via email and social media, encouraging onward sharing. We used closed and open-ended questions related to policy and program information concerning the regulation, availability, target population, indications, implementation, benefits, and challenges of COVID-19 self-testing (C19ST). We defined self-testing as tests performed and interpreted by an untrained individual, often at home. Descriptive summaries, cross-tabulations, and proportions were used to calculate outcomes at the global level and by WHO region and World Bank income classifications.

Results

Between 01 and 11 February 2022, 844 individuals from 139 countries responded to the survey, with 45% reporting affiliation with governments and 47% operating at the national level. 504 respondents from 101 countries reported policies supporting C19ST for a range of use cases, including symptomatic and asymptomatic populations. More respondents from low-and-middle-income countries (LMICs) than high-income countries (HICs) reported a lack of an C19ST policy (61 vs 11 countries) and low population-level reach of C19ST. Respondents with C19ST experience perceived that the tests were mostly acceptable to target populations, provided significant benefits, and highlighted several key challenges to be addressed for increased success. Reported costs varied widely, ranging from specific programmes enabling free access to certain users and others with high costs via the private sector.

Conclusion

Based on the survey responses, systems for the regulatory review, policy development and implementation of C19STappeared to be much more common in HIC when compared to LIC

in early 2022, though most respondents indicated self-testing was available to some extent (101 out of 139 countries) in their country. Addressing such global inequities is critical for ensuring access to innovative and impactful interventions in the context of a public health emergency of international concern. The challenges and opportunities highlighted by survey respondents could be valuable to consider as future testing strategies are being set for outbreak-prone diseases.

Introduction

42

43

44

45

46

47

48

49

50

51

52

53

54

55

56

57

58

59

60

61

62

The emergence of SARS-CoV-2, the virus responsible for COVID-19, was declared a pandemic by the World Health Organization (WHO) in January 2020 (1). Since then, COVID-19 has caused social, human, and economic crises globally, leading to an accelerated drive for the development of interventions, including diagnostic testing (2). In particular, the pandemic put unprecedented strain on global health systems, leading to an urgent need for rapid and accessible testing modalities particularly in low- and middle-income countries (LMICs). This resulted in the widespread adoption of antigen-based rapid diagnostic tests (Ag-RDTs), which can affordably provide same-day results, early diagnosis, and prompt referrals to onward services and care, including quarantine or treatment, to protect the most vulnerable (3). C19ST was thought to reduce absenteeism at work, made people feel safer and increased uptake and identification of new cases (3). Despite ongoing transmission of SARS-CoV-2 globally, confirmed cases represent only a fraction of the number of infections, with access to testing being a major factor influencing case confirmation rates (4). While laboratory-based polymerase chain reaction (PCR) tests

perpetuity.

It is made available under a CC-BY 4.0 International license.

were initially the gold standard for COVID-19 diagnostic testing, the development of (Ag-

RDTs) provided an accurate, cost-effective and easily accessible alternative(5).

The advent of portable, easy-to-use, and stable Ag-RDTs has rapidly expanded access to testing, opened the possibility of self-testing, and expanded the scope and potential of self-care. Self-testing has been an important intervention recommended by WHO across many different disease areas, including HIV, viral hepatitis, and STIs, particularly in low- and middle-income countries (6,7). Self-testing has consistently been shown to increase access to and uptake on testing overall and can greater uptake of both prevention and treatment services (8,9). While the use of self-testing is increasingly available and well-accepted (10,11), it is important to understand the experiences and views in the context of COVID-19 We conducted a survey targeting policy makers, researchers, and implementers to generate a global understanding of policies and experiences with SARS-CoV-2 AgRDTs for self-testing. Our findings informed the development of WHO guidelines and serve as a future reference point as global policies and practices continue to evolve.

METHODOLOGY

Study design

- We conducted a cross-sectional study using a self-administered electronic questionnaire from
- 81 1st-11th February 2022.

Setting and Participants

Our target participants were policy makers, implementers, and academics from all WHO

member states. The survey questionnaire was disseminated globally by the WHO to gather

perpetuity.

It is made available under a CC-BY 4.0 International license .

responses from a diverse range of participants, including through country and regional office focal points, through social media (e.g. Facebook, twitter, LinkedIn) and professional networks and associations. To ensure a wide distribution, we shared the survey through professional networks via email and social media, encouraging onward sharing.

Data collection tool

We developed the survey questionnaire in SurveyMonkey, which included questions relevant to participants' understanding or perceptions of current policy, practice, and progress of implementing COVID-19 AgRDT in their settings. The questionnaire focused on AgRDT use in general, and we restricted our analysis to questions that focused on self-testing. We designed questions to focus on the following areas: current availability of C19ST regulatory processes, policy, and use, target population for C19ST, national coverage and willingness of the target population to undertake C19ST, requirements and mechanisms for reporting C19ST results according to policy or practice, mechanisms and costs for accessing C19ST kits according to policy or practice, and benefits and challenges of implementing C19ST.

Key variables

We defined self-testing as tests performed and interpreted by an untrained individual, typically at home. Respondents provided their characteristics, including country of operation, affiliation, and level of involvement in the COVID-19 response. We asked respondents both closed and open-ended questions related to policy and program information concerning the regulation, availability, target population, indications, implementation, benefits, and challenges of COVID-19 self-testing. Respondents answered questions they were able to and not all respondents answered all questions.

perpetuity.

It is made available under a CC-BY 4.0 International license .

Statistical methods

We summarized the data using both tabular and graphical descriptive statistics. For tables, we reported the number (n) of responses for each question without missing values, the size of the analysis population (N) and calculated the proportions (n/N). We prepared crosstabulations and produced grouped bar charts of key outcomes to show proportions stratified by variables such as WHO region and country income level classification. We reported the data at a global level and by WHO region and income classifications. We also performed some analyses at the individual respondent level, and others by at the country level regardless of the number of individuals. We conducted all data cleaning and analyses using the R language for statistical computing.

Ethics statement

This study was conducted with a strong commitment to ethical considerations. The survey, disseminated globally via online platforms, ensured voluntary participation. While no explicit informed consent was obtained, the purpose of the survey was clear to all participants. Some identifiable data was collected; however, participants' anonymity was strictly maintained during data management analysis and reporting; and no individual identities will be disclosed or compromised.

RESULTS

Respondents' characteristics

From 1 to 11 February 2022, the survey received 844 responses from individuals in 139 countries. Table 1 describes the characteristics of the respondents, including their representation across all WHO regions and income classifications.

Number of who respondents (n)	831	100%				
WHO Region of Respondents' Country						
African	229	27.2%				
Americas	80	9.5%				
Eastern Mediterranean	64	7.6%				
European	176	20.9%				
South-East Asian	120	14.3%				
Western Pacific	173	20.5%				
World Bank Income Classification of Country						
Low income	74	9%				
Lower middle income	424	51%				
Upper middle income	134	16%				
High income	199	24%				
Level Of Involvement in the COVID-19 Response	Level Of Involvement in the COVID-19 Response					
National level	390	47%				
Regional/provincial/District level	223	27%				
Community level	135	16%				
Other	83	10%				
Affiliation						
Academic	85	10%				
Government	378	45%				
NGO	167	20%				
Private sector	92	11%				
Other	109	13%				

Table 1. Characteristics of survey respondents

129

130

131

132

133

134

135

136

Of the respondents, 45% identified as government officials, and 47% reported involvement in implementing SARS-CoV-2 activities at the national level.

Current availability of C19ST regulatory processes, policy and use

Table 2 outlines the availability of C19ST regulatory processes, policy, and use, as reported by 294 respondents from 92 countries across all regions at the time of the survey (early Feb 2022).

It is made available under a CC-BY 4.0 International license 8

	Does y	our country ha	Are SARS-CoV-2 Ag- RDTs used for self- testing in your country?					
	n	Policy in place, Supportive	Policy in place, not supportive	No policy, but Piloting	Developing policy	No policy, no pilot	Yes (n/N)	percent
All respondents	481	29%	5%	11%	17%	37%	259/481	54%
WHO Region of Res	pondents	' Country						
African	137	15%	2%	7%	21%	55%	30/137	22%
Americas	35	34%	3% 6%		6% 51%		25/36	69%
Eastern Mediterranean	39	21%	5%	18%	13%	44%	24/38	63%
European	78	49%	8%	14%	10%	19%	67/77	87%
South-East Asian	80	31%	8%	14%	8%	40%	39/82	48%
Western Pacific	112	33%	4%	13%	30%	20%	74/114	65%
World Bank Income	Classifica	tion of Respon	dents' Count	ry				
Low income	92	12%	4%	12%	12%	60%	23/96	24%
Lower middle income	241	24%	4%	13%	25%	34%	121/247	49%
Upper middle income	57	28%	4%	9%	19%	40%	35/58	60%
High income	79	59%	5%	9%	3%	24%	72/83	87%

Table 2. Reported availability of C19ST regulatory processes, policy, and use

Most respondents reported that their countries had a regulatory process in place for reviewing and approving C19ST kits. Specifically, 32% (278) of respondents from 81 countries reported that their countries had a C19ST policy in place or was actively developing one. Notably, a lack of policy was reported more frequently by respondents from Low and Middle-income countries (LMIC) nations (25.2%) than by those from high-income nations (10.1%). Respondents from high-income countries were more likely to report that C19ST was used in their country compared to those from low- and middle-income countries (88% vs 19%).

Target population for C19ST

251 respondents from 15 countries reported targeting four specific populations for COVID-19 self-testing, of respondents who provided answers there was a range of different populations noted as being targeted for the use of self-tests which included testing symptomatic

150 individuals and then asymptomatic testing was noted in workplaces, in educational 151 institutions and to support attendance at gatherings.

National coverage and willingness of target population to undertake C19ST

Nationwide implementation of C19ST was reported by 148 respondents from 79 countries, of which 34% were high-income and 65% were LMIC (13.5% Low income, 27.8% = Lower Middle, 21.5% = Upper Middle).

	рори	What proportion of your national population do you estimate has used C19ST?				Based on your experience, how willing are the target populations to use C19ST?					
	n	<1%	1- 20%	20- 50%	>50%		n	Very willing	Willing	Somewhat willing	Not at all willing
All respondents (n = 134)	134	19%	33%	29%	19%		152	41%	30%	25%	3%
WHO Region of Res	sponder	nts' Co	untry								
African	15	27%	20%	33%	20%		18	44%	50%	6%	0%
Americas	9	11%	56%	11%	22%		9	44%	22%	33%	0%
Eastern Mediterranean	10	60%	10%	20%	10%		14	50%	7%	43%	0%
European	30	0%	13%	40%	47%		34	38%	38%	15%	9%
South-East Asian	29	28%	48%	17%	7%		31	35%	23%	42%	0%
Western Pacific	41	15%	41%	34%	10%		46	43%	30%	22%	4%
World Bank Income	e Classif	ication	of Res	pondents	' Country	У					
Low income	16	50%	31%	13%	6%		17	29%	41%	29%	0%
Lower middle income	67	22%	43%	25%	9%		74	41%	24%	31%	4%
Upper middle income	17	6%	24%	65%	6%		19	37%	37%	26%	0%
High income	34	3%	18%	26%	53%		38	47%	34%	13%	5%

156 Table 3. Respondents' perception of national coverage and willingness of target population

157 to use self-tests

152

153

154

155

perpetuity.

It is made available under a CC-BY 4.0 International license .

158

159

160

161

162

163

164

165

166

167

168

169

170

171

172

173

174

175

176

177

178

179

Fig 2B. Cost for accessing C19 kits

The majority of respondents noted that less than half the national population is estimated to have used C19ST, with the highest perception of use reported by respondents from the European region and in High-Income Countries. Respondents from HICs reported more widespread use of C19ST than those from low- and middle-income countries (LMICs). For both LMICs and HICs, 33.3% reported C19ST national coverage between 20 to 50%. In LMICs, 23.5% reported a C19ST reach of less than 1%, while in HICs only 4.8% reported a less than 1% coverage of C19ST. Most respondents across all regions perceived that the target populations were either very willing or willing to use self-tests. Willingness to self-test was consistent between high- and low-income country categories. Requirements and mechanisms for reporting C19ST results according to policy and practice Figure 1A and 1B presents results on requirements and mechanisms for reporting C19ST results according to policy or practice. Fig 1A. Requirements for reporting C19ST results Fig 1B. Mechanisms for reporting results Reporting of positive C19ST results was more common, but it was not required in some regions. In both high- and low-income countries, mechanisms for reporting results included in person, by phone, mobile application, and using a website. Mechanisms and costs for accessing C19ST kits according to policy and practice Figure 2A and 2B outlines the mechanisms and costs for accessing C19ST kits, as reported by 222 respondents. Fig 2A. Distribution methods for C19ST

The most common distribution method for C19ST kits was through pharmacies (47.3%). Direct consumer costs for purchasing C19ST kits varied substantially across respondents and by country, but 58 respondents from 31 countries indicated that C19ST was free for some endusers. Free access to C19ST was reported more frequently in high-income countries than in low-income countries (37.1% vs 18.1%).

Perceived benefits, challenges, and areas of improvement

Respondents reported several challenges related to implementing C19ST, including insufficient infrastructure for distribution and storage of C19ST, poor understanding of how to use and interpret the tests, lack of training for personnel, and lack of awareness among the public about the availability and benefits of C19ST. Respondents were also asked about potential solutions to the challenges identified. Many respondents recommended increased training and education on C19ST, including proper usage and interpretation of results, as well as addressing issues related to distribution and storage of C19ST. Other suggestions included increasing public awareness about the availability and benefits of C19ST, making C19ST more affordable or providing free access, and increasing international cooperation to address the global shortage of C19ST. Other benefits of implementing C19ST that were mentioned included increased confidence in identifying and controlling outbreaks, increased accuracy in identifying cases, and potential reduction in the burden on healthcare systems.

Discussion

180

181

182

183

184

185

186

187

188

189

190

191

192

193

194

195

196

197

198

199

200

201

This cross-sectional study assessed the extent of policy and implementation of COVID-19 selftesting according to perceptions of targeted policy makers, implementers, and researchers contributing to various levels of COVID-19 response as of early 2022. Good survey de avallable di idei

participation globally; supportive policy and more wide use reported in HIC compared to LIC or LMIC – also differences across regions. On the other hand, there was high willingness to use self-tests irrespective of income classification. Wide range of distribution approaches reported with pharmacy/retail generally the most frequent; reported costs ranged widely with free tests more available in HIC than in Low- and Middle-Income Countries. the reported cost of accessing C19ST kits was variable, ranging from free to very costly (e.g. over USD 20). Reporting requirements and mechanisms also varied – generally increased expectation to report positive results but a high proportion of respondents did note no known reporting requirements. Supportive policy across a range of use cases was overwhelmingly reported by most countries globally.

At the time of the survey there were no WHO guidelines on C19ST, our study played a role in highlighting the global inequalities in access to COVID-19 interventions, with wider coverage and access to C19ST reported in high-income countries compared to low- and middle-income countries. An alternative explanation to the global differences in C19ST utilisation between the global South and North could be lack of awareness and policy. Europe, which has the highest proportion of population with access, had the highest proportion of respondents reporting availability of policy. This highlights the role of a WHO guideline in increasing global awareness and utilisation of interventions. The recently released global guidance on C19ST is expected to support development of national policies.

While self-testing can be beneficial as it enables access without requiring action from overstretched professional health workers; and can be more convenient without requiring

ie avaliable uriuei

225

226

227

228

229

230

231

232

233

234

235

236

237

238

239

240

241

242

243

244

245

246

247

13

individuals to go to a health care facility. The widely reported supportive policy and use of C19ST across a range of settings is likely to reflect the acceptable diagnostic performance (12,13) and potential for scalability of this rapid testing technology, which are critical to the COVID-19 pandemic response. COVID-19 Ag RDTs can be produced much faster, cheaper and in large quantities for large scalability. Antigen tests offer the possibility of rapid, inexpensive detection of SARS-COV-2 (14). Community engagement with relevant stakeholders is crucial to successful COVID-19 implementation and scale up (6,15,16). Such community-led approaches have been found to be highly effective when adapted for HIV self-testing (17), and should be considered and adapted as part of future pandemic preparedness plans(18). The study showed a wide range of target populations in both asymptomatic and symptomatic individuals and in either non healthcare, education institution, and mass gatherings settings using C19 ST. The wide range of target populations within and across regions demonstrates wide applicability and the ease of use in place of professional testing. The versatility of C19ST is critical during the COVID-19 pandemic when health systems are stretched for human resource. This is especially important for low-income countries where the diagnostic testing gap is widest in part secondary to financial and human resource challenges. Self-testing using Ag-RDTs can be utilised for triage or identifying individuals with the highest viral load(19). Willingness to self-test was consistent across region and income setting. The willingness of target population is encouraging but not surprising because of the individual and community benefits of C19ST. Unlike professional testing, which may require a visit to a health facility, C19ST like most self-care interventions, allows users to know their ade avallable dildel

status within 30 minutes and without leaving their home. C19ST therefore limits contact with other people and speeds up commencement of post-test actions, including those related to protecting the health of the user, their family and their community. Moderate or severely symptomatic individuals may quickly see the need to access COVID-19 hospital care. Individuals who test negative, seamlessly resume usual activities, or decide to seek alternative clinical care if sick. Other studies support high perceived willingness to use C19 self-testing (7,20,21).

The study reported wider coverage and access use of C19 self-testing from high Income countries compared to low- and middle-income countries. The striking differences in coverage and access to C19ST between high- and low-income nations reflects substantial global inequalities with respect to access to COVID-19 interventions. The strong correlation between GDP and testing capacity was initially driven by the centralised nature and high capital requirements of PCR testing. While C19ST offers the opportunity for wider access based on the affordability of AgRDTs, the survey results suggest that there are still some underlying barriers to full utilisation that need to be addressed in low income countries. To address this gap, greater efforts are needed moving forward to ensure LMICs have access to critical innovations and interventions during public health emergencies and pandemics.

The perceived challenges highlighted by respondents including users' inability to perform or interpret C19ST, false positive results, false negative results, people being forced to self-test, failure to report results, and failure to present for confirmatory testing must be taken into consideration when developing national C19ST strategies or policies. Other studies resonate

15

de avallable di idei a

271

272

273

274

275

276

277

278

279

280

281

282

283

284

285

286

287

288

289

290

291

292

similar challenges on self-testing observed (8,15) from other disease program particularly HIV.

To address the main barrier to perform or accurately translate results, involving the

community in co-creation and dissemination of education materials would be beneficial. In

addition, some literature recommends inclusion of health promotion, layman's language and

public sensitization to increase implementation success of C19ST use (22,23) while users in

other studies recommended locally translated and easily accessible materials through online

or in person (8). As with other self-testing approaches, programmatic support including

engagement with health workers, community groups and those most affected are needed to

achieve the greatest impact. Future strategies using C19ST should consider how to adapt

materials from other self-testing programmes and services. This may improve both

acceptable and feasibility of implementation, as well as maximize limited resources.

Although the survey provides valuable insights into COVID-19 policies and practices, it is essential to consider its limitations. The survey does not necessarily reflect the official positions of countries and ministries of health but rather presents the perspectives of a diverse group of respondents involved in COVID-19 work across countries. Additionally, the findings represent a snapshot of policy and practice as of February 2022 and may not reflect earlier or later circumstances as the pandemic and response continue to evolve. Nevertheless, these findings importantly highlight the views and experiences with C19ST from many countries experiencing outbreaks and reporting high case rates. Thus, the findings may be applicable for future planning in the event of outbreaks or seasonal spread.

The use of Ag-RDTs for self-testing is a promising solution, but our finding of limited access in low-and-middle-income countries compared to high-income countries highlights the harsh reality of global inequalities and the need to address them sustainably. Experiences shared by respondents highlighted benefits and challenges and opportunities that can inform development of effective policies to support self-testing at national and global levels. Moving forward as part of pandemic preparedness, global stakeholders need to prioritize investment to enable LMICs to benefit from critical innovations and interventions.

Acknowledgements

293

294

295

296

297

298

299

300

301

302

303

304

305

306

We would like to thank all participants of the survey and everyone who supported the distribution. We acknowledge WHO guideline development group and colleagues for their untiring feedback throughout the whole process.

WHO Director-General's opening remarks at the media briefing on COVID-19

Reference

1.

307 [Internet]. 2020. Available from: https://www.who.int/director-308 general/speeches/detail/who-director-general-s-opening-remarks-at-the-media-309 briefing-on-covid-19---11-march-2020 310 2. Ko JY, Danielson ML, Town M, Derado G, Greenlund KJ, Kirley PD, et al. Risk Factors 311 for Coronavirus Disease 2019 (COVID-19)—Associated Hospitalization: COVID-19— 312 Associated Hospitalization Surveillance Network and Behavioral Risk Factor Surveillance System. Clin Infect Dis [Internet]. 2021 Aug 4;72(11):e695–703. Available 313 from: https://academic.oup.com/cid/article/72/11/e695/5908300 314

315	3.	Brümmer LE, Erdmann C, Tolle H, McGrath S, Olaru ID, Katzenschlager S, et al. The
316		clinical utility and epidemiological impact of self-testing for SARS-CoV-2 using antigen
317		detecting diagnostics: a systematic review and meta-analysis. medRxiv [Internet].
318		2022;2022.07.03.22277183. Available from:
319		http://medrxiv.org/content/early/2022/07/05/2022.07.03.22277183.abstract
320	4.	Bobrovitz N, Arora RK, Cao C, Boucher E, Liu M, Donnici C, et al. Global
321		seroprevalence of SARS-CoV-2 antibodies: A systematic review and meta-analysis.
322		Khudyakov YE, editor. PLoS One [Internet]. 2021 Jun 8;16(6):e0252617. Available
323		from: https://dx.plos.org/10.1371/journal.pone.0252617
324	5.	Organization WH. Diagnostic testing for SARS-CoV-2: interim guidance [Internet].
325		2020. Available from: https://apps.who.int/iris/handle/10665/334254
326	6.	WHO. Recommendations and guidance on hepatitis C virus self-testing. 2021. 20 p.
327	7.	WHO. Use of SARS-CoV-2 antigen-detection rapid diagnostic tests for COVID-19 self-
328		testing. Interim Guid. 2022;(9 March):1–16.
329	8.	Jamil MS, Eshun-Wilson I, Witzel TC, Siegfried N, Figueroa C, Chitembo L, et al.
330		Examining the effects of HIV self-testing compared to standard HIV testing services in
331		the general population: A systematic review and meta-analysis. EClinicalMedicine
332		[Internet]. 2021;38:100991. Available from:
333		https://doi.org/10.1016/j.eclinm.2021.100991
334	9.	Organization WH. WHO implementation tool for pre-exposure prophylaxis (PrEP) of
335		HIV infection: module 10: testing providers [Internet]. Geneva: World Health
336		Organization; 2017 Aug. Available from:
337		https://apps.who.int/iris/handle/10665/258516

338 Fonner VA, Luhmann N, Siegfried N, Johnson C, Baggaley R, Ford N, et al. Use of 10. 339 indirect evidence from HIV self-testing to inform the WHO hepatitis C self-testing recommendation. BMJ Glob Heal. 2023;8(2):2022-4. 340 341 11. Kiptinness C, Kuo AP, Reedy AM, Johnson CC, Ngure K, Wagner AD, et al. Examining 342 the Use of HIV Self-Testing to Support PrEP Delivery: a Systematic Literature Review. 343 Curr HIV/AIDS Rep [Internet]. 2022;19(5):394–408. Available from: https://doi.org/10.1007/s11904-022-00617-x 344 345 Zwart VF, van der Moeren N, Stohr JJJM, Feltkamp MCW, Bentvelsen RG, Diederen 12. 346 BMW, et al. Performance of Various Lateral Flow SARS-CoV-2 Antigen Self Testing 347 Methods in Healthcare Workers: a Multicenter Study [Internet]. Infectious Diseases 348 (except HIV/AIDS); 2022 Jun. Available from: http://medrxiv.org/lookup/doi/10.1101/2022.01.28.22269783 349 Stohr JJJM, Zwart VF, Goderski G, Meijer A, Nagel-Imming CRS, Kluytmans-van den 350 13. 351 Bergh MFQ, et al. Self-testing for the detection of SARS-CoV-2 infection with rapid 352 antigen tests [Internet]. Public and Global Health; 2021 Jun. Available from: 353 http://medrxiv.org/lookup/doi/10.1101/2021.02.21.21252153 354 14. Peeling RW, Olliaro PL, Boeras DI, Fongwen N. Scaling up COVID-19 rapid antigen tests: promises and challenges. Lancet Infect Dis [Internet]. 2021 Jun 8;21(9):e290-5. 355 356 Available from: https://linkinghub.elsevier.com/retrieve/pii/S1473309921000487 357 15. Nwaozuru U, Obiezu-Umeh C, Diallo H, Graham D, Whembolua G-L, Bourgeau MJ, et 358 al. Perceptions of COVID-19 Self-Testing and Recommendations for Implementation and Scale up Among Black/African Americans: Implications for the COVID-19 STEP 359 Project [Internet]. In Review; 2022 Jun. Available from: 360

361 https://www.researchsquare.com/article/rs-1277219/v1 362 16. Figueroa C, Johnson C, Verster A, Baggaley R. Attitudes and Acceptability on HIV Selftesting Among Key Populations: A Literature Review. AIDS Behav [Internet]. 2015 Aug 363 4;19(11):1949-65. Available from: http://link.springer.com/10.1007/s10461-015-364 365 1097-8 366 Sibanda EL, Neuman M, Tumushime M, Mangenah C, Hatzold K, Watadzaushe C, et al. 17. 367 Community-based HIV self-testing: a cluster-randomised trial of supply-side financial 368 incentives and time-trend analysis of linkage to antiretroviral therapy in Zimbabwe. 369 BMJ Glob Heal [Internet]. 2021 Aug 4;6(Suppl 4):e003866. Available from: https://gh.bmj.com/lookup/doi/10.1136/bmjgh-2020-003866 370 371 Seale H, Harris-Roxas B, Heywood A, Abdi I, Mahimbo A, Chauhan A, et al. Speaking 18. 372 COVID-19: supporting COVID-19 communication and engagement efforts with people from culturally and linguistically diverse communities. BMC Public Health [Internet]. 373 2022 Jun 18;22(1):1257. Available from: 374 375 https://bmcpublichealth.biomedcentral.com/articles/10.1186/s12889-022-13680-1 376 19. Porte L, Legarraga P, Iruretagoyena M, Vollrath V, Pizarro G, Munita J, et al. 377 Evaluation of two fluorescence immunoassays for the rapid detection of SARS-CoV-2 antigen—new tool to detect infective COVID-19 patients. PeerJ [Internet]. 2021 Jun 378 379 9;9:e10801. Available from: https://peerj.com/articles/10801 380 20. Hall EW, Luisi N, Zlotorzynska M, Wilde G, Sullivan P, Sanchez T, et al. Willingness to 381 Use Home Collection Methods to Provide Specimens for SARS-CoV-2/COVID-19 Research: Survey Study. J Med Internet Res [Internet]. 2020 Aug 4;22(9):e19471. 382 Available from: https://www.jmir.org/2020/9/e19471 383

20

384	21.	Goggolidou P, Hodges-Mameletzis I, Purewal S, Karakoula A, Warr T. Self-Testing as
385		an Invaluable Tool in Fighting the COVID-19 Pandemic. J Prim Care Community Health
386		[Internet]. 2021 Jun 8;12:215013272110477. Available from:
387		http://journals.sagepub.com/doi/10.1177/21501327211047782
388	22.	Van den Broucke S. Why health promotion matters to the COVID-19 pandemic, and
389		vice versa. Health Promot Int [Internet]. 2020 Aug 4;35(2):181–6. Available from:
390		https://academic.oup.com/heapro/article/35/2/181/5820891
391	23.	Coste AT, Egli A, Greub G. Self-testing for SARS-CoV-2: Importance of lay
392		communication. Swiss Med Wkly. 2021;151(21–22):2–5.
393		




Fig 1A




Fig 1B




Fig 2A

< 1\$	Malawi	Indonesia						
1-2\$	South Korea	Malaysia	Pakistan					
2-5\$	Portugal	Vietnam	Germany					
	India	Netherlands	Thailand					
	Singapore	Belgium						
5-10\$	Canada	Spain	Cyprus					
	Mauritius	Qatar	Finland					
	Peru	Bahrain						
10-20\$	Australia	Mexico	Ukraine					
20\$+	Russia	USA	Papua New Guinea					
	Philippines							
Fig 2B								
ΠB	20							